Factors Preventing Warfarin from Achieving Therapeutic INR
Multiple factors can prevent warfarin from reaching therapeutic INR, with medication non-adherence being the most common cause (41.8% of cases), followed by drug interactions (particularly enzyme inducers like rifampin, phenobarbital, and carbamazepine), high dietary vitamin K intake, and malabsorption disorders 1, 2.
Primary Causes of Subtherapeutic INR
Patient-Related Factors
- Non-adherence to therapy is the single most important factor interfering with therapeutic INR control 2
- Dietary vitamin K intake: High consumption of vitamin K-rich foods (leafy greens, certain vegetables) antagonizes warfarin's effect 1
- Unusual sources: Smokeless tobacco contains high vitamin K levels and can cause warfarin resistance even at doses up to 30 mg daily 3
Drug Interactions That Decrease INR
The FDA label identifies specific medications that reduce warfarin effectiveness through enzyme induction 1:
Strong enzyme inducers:
- Rifampin (most potent)
- Carbamazepine
- Phenobarbital and other barbiturates
- Phenytoin
- Griseofulvin
Other medications:
- Cholestyramine (blocks intestinal absorption - space warfarin 2 hours before or 6 hours after)
- Nafcillin
- Azathioprine
- St. John's wort and Coenzyme Q10 (herbal products) 1
Notably, some antiretroviral agents like ritonavir paradoxically require higher warfarin doses despite being CYP3A4 inhibitors, due to concomitant CYP2C9 induction 4.
Medical Conditions
Endogenous factors that decrease INR 1:
- Hypothyroidism (slows warfarin metabolism)
- Edema and nephrotic syndrome
- Hyperlipidemia
- Hereditary coumarin resistance
Absorption Issues
Gastroparesis is an overlooked but significant cause of fluctuating INR, as delayed gastric emptying leads to unpredictable warfarin absorption 5. Consider gastric motility testing in patients with erratic INR despite documented compliance.
Clinical Approach
When encountering subtherapeutic INR:
- First verify compliance - this accounts for nearly half of all cases
- Review all medications including over-the-counter drugs, herbals, and recent additions/discontinuations
- Assess dietary patterns - specifically vitamin K intake and any recent dietary changes
- Check for malabsorption - diarrhea, steatorrhea, or gastrointestinal disorders
- Consider gastroparesis if INR fluctuates wildly despite compliance
Important Caveats
For a single subtherapeutic INR in previously stable patients: The ACCP guidelines recommend against routine bridging with heparin and suggest continuing the current warfarin dose with repeat INR in 1-2 weeks 6. This applies when INR is only 0.5 below therapeutic range.
Major warfarin drug interactions at hospital discharge are associated with 36% increased odds of nontherapeutic INR (aOR 1.36,95%CI: 1.11-1.67) and may serve as markers for patients requiring closer monitoring 7.
The presence of comorbidities and warfarin duration <12 months are also significantly associated with subtherapeutic INR 8. Nearly 85% of patients have time in therapeutic range <60%, highlighting the difficulty of warfarin management even in tertiary care settings 8, 2.